Economic impacts attributable to the early clinical benefit of atorvastatin therapy - A US managed care perspective

Current Medical Research and Opinion

Volumn 23, Issue 7, 2007, Pages 1517-1529

  Straka, Robert J ^a   Mamdani, Muhammad ^b   Damen, Joep ^c   Kuntze, C Erik E ^b   Liu, Larry Z ^b   Botteman, Marc F ^d,f   Koren, Michael J ^e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b PFIZER INC   (United States)

^c PHARMERIT INTERNATIONAL   (Netherlands)

^d PHARMERIT INTERNATIONAL   (United States)

^e Jacksonville Center for Clinical Research   (United States)

^f NONE   (United States)

Author keywords

Atorvastatin; Cardiovascular disease; Cost analyses; Cost benefit analysis; Managed care programs; Simvastatin

Indexed keywords

ATORVASTATIN; GENERIC DRUG; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG EFFICACY; ECONOMIC ASPECT; HEALTH CARE ORGANIZATION; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MANAGED CARE; MONTE CARLO METHOD; MULTIVARIATE ANALYSIS; PREVALENCE; RISK FACTOR; UNITED STATES; UNIVARIATE ANALYSIS;

ANGINA, UNSTABLE; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CORONARY DISEASE; COSTS AND COST ANALYSIS; DIABETES MELLITUS; DRUG COSTS; FEMALE; HEPTANOIC ACIDS; HUMANS; MALE; MODELS, THEORETICAL; PYRROLES; SIMVASTATIN; UNITED STATES;

EID: 34547210808     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X199808     Document Type: Article

References (60)

1. Center for Disease Control and Prevention (CDC). Deaths: preliminary data for 2004. Available from http://www.cdc.gov/nchs/products/pubs/pubd/hestats/ prelimdeaths04/preliminarydeaths04.htm [Last accessed Aug 21, 2006]
2. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:e85-151
3. Wiviott SD, de Lemos JA, Cannon CP, et al. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation 2006;113:1406-14
4. Liebson PR. CARDS and A to Z. Prev Cardiol 2005;8:59-62
5. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-16
6. Heart protection study collaborative group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
7. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
8. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006;48:438-45
9. Topol EJ. Intensive statin therapy - a sea change in cardiovascular prevention. N Engl J Med 2004;350:1562-4
10. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
11. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-8
12. Schwartz GG, Olsson AG, Szarek M, et al. Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes Care 2005;28:2508-13
13. Colhoun HM, Betteridge DJ, Durrington PN, et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2005;48:2482-5
14. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96
15. Sever PS, Poulter NR, Dahlof B, et al. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Am J Cardiol 2005;96:39F-44
16. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58
17. Novela C, Hennekens CH. Hypothesis: atorvastatin has pleiotropic effects that translate into early clinical benefits on cardiovascular disease. J Cardiovasc Pharmacol Ther 2004;9:61-3
18. Nissen SE. High-dose statins in acute coronary syndromes: not just lipid levels. JAMA 2004;292:1365-7
19. Sakabe K, Fukuda N, Wakayama K, et al. Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia. Am J Cardiol 2004;94:497-500
20. Ray KK, Cannon CP, McCabe CH, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005;46:1405-10
21. McKenney JM, Davidson MH, Jacobson TA, et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006;97:89C-94
22. IMS Health. 2004 year-end US prescription and sales information and commentary. Available from http://www.imshealth.com [Last accessed Aug 21, 2006]
23. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423
24. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005;19:117-25
25. Garcia MJ, Reinoso RF, Sanchez Navarro A, et al. Clinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol 2003;25:457-81
26. Patel TN, Shishehbor MH, Bhatt DL. A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. Eur Heart J 2007;28:664-72 [Epub ahead of print 22 Jan 2007]
27. Fichtlscherer S, Schmidt-Lucke C, Bojunga S, et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur Heart J 2006;27:1182-90
28. O'Donghue M, Morrow DA, Sabatine MS, et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 2006;113:1745-52
29. Ray KK, Cannon CP. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects? Am J Cardiol 2005;96:54F-60
30. Nissen SE. Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am J Med 2005;118(Suppl 12A):22-7
31. Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Atheroscler Suppl 2004;5:81-7
32. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9
33. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7
34. Serruys PW, De Feyter PJ, Benghozi R, et al. The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease. Int J Cardiovasc Intervent 2001;4: 165-72
35. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45
36. Center for Disease Control and Prevention (CDC) and National Center for Health Statistics. National Hospital Discharge Survey Description. Available from http://www.cdc.gov/nchs/about/major/hdasd/nhdsdes.htm [Last accessed Feb 26, 2007]
37. Center for Disease Control and Prevention (CDC) and National Center for Health Statistics. National Health and Nutrition Examination Survey. Available from http://www.cdc.gov/nchs/nhanes.htm [Last accessed Feb 26, 2007]
38. Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2004;164:1427-36
39. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-7
40. Samsa GP, Matchar DB, Memisoglu A, et al. The cost of treating stroke: changes from 1991 to 2001. Dallas, TX: American Heart Association, 2005
41. Stroupe KT. Cost-effectiveness of coronary artery bypass grafts vs. angioplasty for revascularization of high-risk patients [presentation]. Health Economics Research Centre, August 2005
42. Sen SS, Khandker RK, Roth DA, et al. A one-year comparison of cost and outcomes of angioplasty in stent and nonstent patients. Am J Ther 2005;12:210-7
43. DeFrances CJ, Hall MJ. 2002 national hospital discharge survey. Advance data from vital and health statistics; no. 342. 2004. Hyattsville, Maryland: National Center for Health Statistics, 2004
44. Benner JS, Pollack MF, Smith TW, et al. Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. Am J Health Syst Pharm 2005;62: 1468-75
45. Caspard H, Chan AK, Walker AM. Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. Clin Ther 2005;27:1639-46
46. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S), 1998. Atheroscler Suppl 2004;5:99-106
47. Eisenstein EL, Shaw LK, Anstrom KJ, et al. Assessing the clinical and economic burden of coronary artery disease: 1986-1998. Med Care 2001;39:824-35
48. Ballantyne CM, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005;149:464-73
49. Milionis HJ, Rizos E, Kostapanos M, et al. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin 2006;22:1123-31
50. Knopp RH, d'Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006;29:1478-85
51. Koren MJ. Statin use in a 'real-world' clinical setting: aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial. Am J Med 2005;118(Suppl 12A): 16-21
52. Brown AS, Bakker-Arkema RG, Yellen L, et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol 1998;32:665-72
53. Koren MJ, Smith DG, Hunninghake DB, et al. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. Pharmacoeconomics 1998;14:59-70
54. Mihaylova B, Briggs A, Armitage J, et al. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20 536 individuals. Lancet 2005;365:1779-85
55. Lange AP, Szucs TD. Cost-effectiveness of atorvastatin in the early treatment of acute coronary syndromes in Germany based on the MIRACL study [in German]. Med Klin (Munich) 2004;99:500-5
56. Gomez-Gerique JA, Casciano R, Stern L, et al. A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain. Eur J Health Econ 2004;5:278-84
57. Athyros VG, Papageorgiou AA, Symeonidis AN, et al. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. Angiology 2003;54:679-90
58. Walshe V, Nash A, Barry M. Cost effectiveness of statin therapy for the primary prevention of coronary heart disease. Ir Med J 2006;100:144-5
59. Fernandez de Bobadilla J, Lopez de Sa E, Alonso Troncoso I, et al. Cost-effectiveness analysis of the use of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic model of the CARDS study [in Spanish]. An Med Interna 2006;23:213-9
60. Hippisley-Cox J, Cater R, Pringle M, et al. Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices. BMJ 2003;326:689